NDA 050429 · Tp Anda Holdings
Rimactane
Rifampin · Oral
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1971
May 21, 1971
Approved uses
3
Original approval plus efficacy supplements
Registered trials
627
95 Phase 3, 60 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 18, 1976 Supplement 42 · Efficacy
- May 9, 1973 Supplement 29 · Efficacy
- May 21, 1971 Original approval
1 products under this application
- RIMACTANE · RIFAMPIN 300MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rifampin" as an intervention, any sponsor and status, largest first.
- Post ExpOsure Prophylaxis for LEprosy in the Comoros and MadagascarPivotal-lookingCompleted
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT03662022 · 144,000 participants · Start Jan 2, 2019 · Primary completion Jan 17, 2023
Drug: Rifampicin · For: Leprosy
Sites: Anjouan, Comoros; Mohéli, Comoros; Miandrivazo, Madagascar
- Bedaquiline Enhanced Post ExpOsure Prophylaxis for LeprosyPivotal-lookingRecruiting
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT05597280 · 124,000 participants (planned) · Start Mar 22, 2023 · Primary completion Mar 15, 2027
Drug: BE-PEP Bedaquiline; SDR-PEP Rifampicin and 1 more · For: Leprosy
Sites: Moroni, Comoros
- A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of TuberculosisPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00317330 · 6,400 participants · Start Dec 2004
Drug: Isoniazid; Pyrazinamide and 1 more · For: Tuberculosis
Sites: Rio de Janeiro, Brazil
- Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectivenessPivotal-lookingCompleted
McGill UniversityAcademic, hospital or other
NCT00931736 · 6,031 participants · Start Aug 2009 · Primary completion Apr 2017
Drug: Isoniazid; Rifampin · For: Latent Tuberculosis Infection
Sites: Sydney, Australia; Cotonou, Benin; Rio de Janeiro, Brazil · 12 sites in all
- Shortened Regimens for Drug-susceptible Pulmonary TuberculosisPivotal-lookingStatus unknown
Beijing Chest HospitalAcademic, hospital or other
NCT02901288 · 3,900 participants (planned) · Start Aug 2016 · Primary completion Dec 2018
Drug: Isoniazid; Rifampicin and 3 more · For: Tuberculosis, Pulmonary
Sites: Hefei, China; Beijing, China; Chongqing, China · 35 sites in all
- A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)Pivotal-lookingRecruiting
Huashan HospitalAcademic, hospital or other
NCT06022146 · 3,520 participants (planned) · Start Sep 1, 2023 · Primary completion Sep 1, 2026
Drug: isoniazid and rifapentine; Rifampin and Isoniazid · For: Tuberculosis; Latent Tuberculosis
Sites: Anshun, China; Bijie, China; Daozhen Klau and Hmong Autonomous County in Zun'yi, China · 66 sites in all
- Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBIPivotal-lookingRecruiting
Centers for Disease Control and PreventionFederal agency
NCT03474029 · 3,400 participants (planned) · Start Aug 1, 2019 · Primary completion Dec 31, 2029
Drug: Rifapentine daily for 6 weeks; Rifapentine and Isoniazid weekly for 12 weeks and 2 more · For: Latent Tuberculosis
Sites: Denver, Colorado; Washington D.C., District of Columbia; Manhattan, New York · 21 sites in all
Affiliated Hospital of Nantong UniversityAcademic, hospital or other
NCT07811518 · 3,000 participants (planned) · Start Aug 15, 2022 · Primary completion Aug 31, 2026
Drug: tuberculosis preventive treatment · For: Latent Tuberculosis Infection (LTBI); Tuberculosis (TB)
Sites: Nantong, China; Meishan, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, et al. · N Engl J Med 2022 · Randomized Controlled Trial
- Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.
Meya DB, Cresswell FV, Dai B, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Tp Anda Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.